IDCRC Investigator Profile: Ralf Duerr, MD, PhD

Ralf Duerr, MD, PhD, is a research associate professor in the Department of Medicine within the NYU Grossman School of Medicine. His research focuses on the functional and genomic dimensions of viral infections, including but not limited to SARS-CoV-2, HIV-1, mpox, and Influenza.

How long have you worked with a VTEU?

I have been officially part of the VTEU since the beginning of 2023, marking two and a half years with the team. However, my collaboration with Dr. Mark Mulligan and the NYU Vaccine Center dates back to before this period. In fact, I was working in the lab next door when we became the 10th nationwide VTEU in 2020. As a result, I have felt a strong connection to the VTEU since 2020.

Briefly describe the IDCRC-supported trials you’ve supported.

At the NYU Vaccine Center, we have a diverse and interconnected team of clinicians, administrators, lab technicians, and researchers who engage in steady collaboration. As an MD-PhD, my earlier work focused more on clinical aspects, but in recent years, I have shifted my focus towards research and assay development. While our Vaccine Center Director, Dr. Mark Mulligan, and his clinical and administrative team efficiently managed several IDCRC studies, I contributed on the research side by providing scientific advice, conducting data analyses, and developing assays.

I have been deeply involved in studies on mpox, Influenza, and COVID-19/Long COVID, where we developed multiplex, high-throughput binding and avidity assays. We have also applied to be a site lab for multiple studies. At NYU, we are leveraging our diverse faculty to integrate serological and cellular assays with clinical aspects of our studies.

Of these trials, what has been the most impactful or highlight of the work?

Some highlights of my recent work include the immunophenotyping of over 2,500 samples from a long COVID cohort and the longitudinal immunophenotyping of Influenza responses against 23 antigens from recent Influenza vaccines, historic Influenza pandemics, and strains with pandemic potential, such as H5N1 clade 2.3.4.4.b. For mpox, following the publication of our vaccine durability study in the NEJM at the end of 2023, we are finalizing broader serological analyses. This includes developing a novel multiplex assay against both monkeypox and vaccinia virus antigens, with serum time points up to two years post-vaccination.

Learn more about IDCRC studies here.

What is a strength or example of the importance of the IDCRC?

As the name Infectious Diseases Clinical Research Consortium (IDCRC) suggests, one of its key strengths is its extensive network of experts in clinical trials and research, both nationally and internationally. This extensive knowledge base, combined with the power to effect change in patient treatment, is what makes the consortium so impactful. For me, this patient-centered focus is essential in making clinical studies truly worthwhile, and the IDCRC exemplifies this priority.

I find the inclusion of human challenge trials within the IDCRC particularly intriguing, as it allows for the determination of key correlates of protection in a highly controlled and monitored research environment. Working and interacting with colleagues within the IDCRC is incredibly fulfilling, and the recent annual meeting showcased the strength and resilience of this well-functioning network. I am optimistic that it will withstand any challenges and continue to thrive.

What do you like to do outside of the VTEU?

Outside of my work with the VTEU through the NYU Vaccine Center, I am also affiliated with the NYU Departments of Medicine and Microbiology. These affiliations place me in a rich research environment with endless opportunities to explore, grow, and push boundaries.

On a personal note, I cherish spending time with my family, especially with my young son, who, for almost two years now, has been a constant reminder to take breaks and see the world through a child's eyes. When time permits, I enjoy traveling, being in nature, exploring new places, and engaging in sports—activities that have become more challenging to fit in with a baby and a demanding career in infectious diseases!

Finally, I want to express my gratitude to the IDCRC for undertaking such essential work. Thank you for the opportunity to participate in this interview. Heartfelt thanks go to my mentors at NYU, including Dr. Mark Mulligan, and all my collaborators for their invaluable support and guidance.